Home News & Events Social media Social media What’s happening in ICON ICON Plc While RWD and tokenisation introduce many efficiencies and benefits to long-term follow-up, there are also extremely stringent requirements for handling the associated data. Find out how to ensure secure long-term foll... 19 Jan View post View webpage ICON Plc On January 5th, 2026, on the occasion of the visit of Irish Prime Minister Mr. Micheál Martin to China, ICON China team attended a business dinner hosted by the Irish government in Beijing. The event was held at the join... 16 Jan View post ICON Plc Missed our recent webinar from Symphony Health, an ICON plc company? The recording for Riding the data wave: How pharma can navigate disruptions in open claims is now available. Discover how life sciences organisatio... 16 Jan View post View webpage ICON Plc Learn the pros and cons of different AI models for SaMDs. The right model and data training sets are essential to develop your AI-enabled device. Our latest whitepaper lays out the best practices for data and AI models... 16 Jan View post View webpage ICON Plc What should you consider when choosing a training dataset for your AI-enabled SaMD? Our whitepaper has the answers. Learn about AI models and data best practices and plan for your FDA Pre-Sub. Download it today. https://... 16 Jan 2 View post View webpage ICON Plc With over 10,000 journals and conferences to consider it’s an important question to answer. There are 50+ accessible points of metadata to use in focusing your selection for a publishing source. Schedule a demo to learn ... 15 Jan View post View webpage ICON Plc Long-term follow-up for vaccines may seem to be a distant concern when clinical trials are just beginning, but it can be critical to have a plan for follow-up at the outset. Learn considerations for follow-up design, s... 15 Jan View post View webpage ICON Plc Potent and long-lasting incretin receptor agonists like GLP-1 RAs target the molecular mechanisms underlying glucose metabolism. Learn why these therapies are ushering in a new era of multi-indication drug development in... 15 Jan View post View webpage ICON Plc Deepali Suri shares her vision for the biotech sector in 2026 and beyond. With over two decades of experience across pharma, biotech, and CROs, she outlines a clear strategy to strengthen innovation, streamline develop... 14 Jan 2 View post View webpage ICON Plc Therapeutic developers can aid control of the HIV epidemic by creating simpler, longer-acting prevention methods that perform better in real-world settings. ICON's whitepaper details these advances and best practices for... 14 Jan 2 View post View webpage ICON Plc Demographic Matching in Organ Impairment Studies: Why It Matters Organ impairment (OI) studies are critical for safe and effective drug development—but did you know that demographic matching can make or break the accurac... 13 Jan View post View webpage ICON Plc In 2025 ICON was recognised in global rankings by both TIME and Fortune magazines celebrating organisations excelling in financial stability and environmental sustainability. Learn more. https://ow.ly/aqkw50XSPP5 13 Jan View post View webpage
